Mental health patient 'sedated' and waiting for days in emergency department
It follows calls by the Nurses' Professional Association of Queensland for an independent investigation into performance reporting data in emergency departments.
In a June survey, nurses from Rockhampton and Gladstone hospitals claimed they were being pressured to manipulate data and raised concerns about the increasing use of sedation on mental health patients.
Boyne Island doctor Gaston Boulanger said his patient was taken by ambulance to the Gladstone Hospital because of his psychosis.
"That's very frightening, very, very troubling for a patient like that. It's not good for their ongoing mental health."
Despite a population of approximately 63, 000 in the Gladstone region, there are no inpatient mental health beds at the Gladstone Hospital.
The Central Queensland Hospital and Health Service acknowledged its emergency departments (ED) were dealing with high demand.
"I am concerned that allegations have been made that ED data has been misrepresented, and I certainly do not endorse incorrect reporting of data in any instance," chief executive Lisa Blackler said.
She also refuted claims that mental health patients were being sedated while waiting for a bed, and said sedation was only used when a patient's behaviour risked themselves, patients or staff.
Nurses' Professional Association of Queensland President Kara Thomas said the union recently surveyed nearly 100 members in Gladstone and Rockhampton.
She said the survey showed nurses were being pressured to move emergency department patients into overflow short-stay units to avoid performance breaches.
"Almost 100 per cent [of respondents] say patients are waiting more than 12 hours in ED frequently to daily, with mental health patients sometimes waiting up to seven days or more for admission, often sedated in non-designated areas," Ms Thomas said.
She also said nurses were treating patients in areas like hallways, because there were no beds available.
A spokesperson for Health Minister Tim Nicholls said he was aware of the union's concerns and the government had allocated $33 billion for health in the state budget to improve the state's health and hospital services.
Ms Thomas said an independent audit into performance reporting data was necessary to understand how to fix the issue.
"Someone is going to die, potentially, and this needs to be actioned."
Ms Blackler said the hospital recognised EDs were not suitable for long-term care and the service is committed to reducing the number of patients spending more than 24 hours in the ED.
She said, while there was longer term planning underway, they had utilised other spaces at both Rockhampton and Gladstone to expand ED beds.
There are 23 mental health beds at the Rockhampton Hospital, which services central and central-west Queensland — a population of more than 200,000.
Dr Boulanger said the Gladstone Hospital desperately needed its services upgraded, including inpatient mental health beds.
The mental health unit in Rockhampton is undergoing a $92 million expansion to increase the number of beds to 32.
It is due to be complete in 2026.
Gladstone has a step-up and step-down mental health facility, which provides a 24-hour residential service for adults needing sub-acute mental health services.
But Dr Gaston said many people were too ill for that level of treatment.
For several years he has also called on the health service to build an ICU at the Gladstone Hospital.
He said it would attract specialists which would improve health outcomes, including in the emergency department.
"For instance, if you have patient who needs to see a cardiologist in Gladstone, the only way is to go to another facility because Gladstone doesn't have a cardiologist," Dr Boulanger said.
"In any other hospital, the cardiologist will come to the ED… they treat the patient, and the patient can go home."
The health service said the region was well serviced by the ICU in Rockhampton, but it is continually monitoring demand.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
SBS Australia
an hour ago
- SBS Australia
Nelli lives with chronic pain. It took her 20 years to find the right help
Nelli Stevenson has been living with chronic pain since she was a teenager — but it has taken her many years, and a serious medical emergency, to find the help she needed. Stevenson, 37, started experiencing chronic pelvic pain, along with a nerve pain called sciatica, when she was around 14 years old. These conditions later worsened after the birth of her child, and became chronic around three years ago. "I live with chronic persistent pain. I've had several medical professionals tell me I'll likely be in pain for the rest of my life," she told SBS News. "There is only so much they can do for me surgically. So, I manage my pain on a day-to-day basis through a number of physical interventions, as well as medical interventions as well." Stevenson works for a community legal service with flexible arrangements, and says she is fortunate to have access to a specialist GP and team who support her physical therapy and pain management. "However, it took me about 20 years of pushing through the medical system, constantly advocating for myself and fighting to be taken seriously, to be able to find that group of people," she said. This started in her late teens. "I was told, like most people with pelvic pain, that it's just part of being a woman, it's part of your period. I was gaslit for several years," she said. This had serious consequences. At one point, Stevenson says she had normalised the chronic abdominal pain she was experiencing that she didn't notice her appendix had ruptured. "I didn't present to hospital until 12 days after it had happened," she said. Stevenson ended up in ICU and needed two major surgeries to save her life. She says these caused significant scar tissue, which added to her chronic pain. She said she has heard many stories of late diagnosis, misdiagnosis and gaslighting from the chronic pain community. "They [medical professionals] aren't taking seriously these people who are saying, 'I cannot live like this anymore. I need more help.'" Chronic pain is taking longer to diagnose in 2025, according to a new report from peak consumer body Chronic Pain Australia . The 11th edition of its National Pain Survey, released on Monday to kick off a week-long awareness campaign, has revealed what it calls a "devastating national crisis" marked by diagnosis delays and a severe mental health toll. Waiting for a diagnosis Chronic pain is a common and complex condition characterised by persistent pain experienced on most days of the week, according to the Australian Institute of Health and Welfare. Approximately one in five Australians, or 3.6 million, live with chronic pain. However, Chronic Pain Australia believes the figure is higher. "That figure came from a study that was done about 15 years ago," Chronic Pain Australia chair Nicolette Ellis said. "What we're predicting chronic pain is sitting at in [terms of] prevalence is about four million Australians in this day and age, and [this is] projected to go up to five million in 2050." Of the almost 5,000 survey respondents, many had multiple conditions, including pain, joint pain and nerve pain, often experienced at the same time. Over half (54 per cent) of respondents reported waiting more than two years for a diagnosis, and 44 per cent waited over three years. This has increased from 42 per cent waiting over three years in 2024, and 41 per cent in 2023. Mental health impacts — and a 'pervasive' stigma Ellis said delayed diagnoses can contribute to the "vicious cycle" of chronic pain, including mental ill health. "For a lot of people, it takes away their identity, increases their mental health issues … and that's because of [what] pain can take away," she said. "If you're waiting for a diagnosis, typically you lose function. That might be reduced hours at work, or it might be leaving the workforce altogether." The report revealed 74 per cent of respondents had experienced mental health impacts, with 87 per cent experiencing sleep disturbances. Among other impacts was 63 and 59 per cent of respondents who experienced strain on family relationships and friendships. Stigma around chronic pain is "pervasive", according to the report, which found 74 per cent reported feeling ignored or dismissed. Ellis said this can come from health professionals along with friends, family, and community members. However, reported stigma from health professionals was higher than overall levels. "Many people feel gaslit or stigmatised by health professionals — that this is all in their head and it's not a true condition," she said. Calls for more complex care Despite the complex nature of chronic pain, the report found access to appropriate multidisciplinary and specialist care is falling short. Only 18 per cent of respondents received a referral to multidisciplinary pain management, and 30 per cent of those referred never secured an appointment. Ellis said access to multidisciplinary care is limited and dependent on location. "If you're in a metropolitan area, usually you can get into a tertiary or hospital-based pain clinic. But they have massive wait lists," she said. "Access to that kind of care is very limited." Chronic Pain Australia has been advocating for integrating multidisciplinary care programs into primary care settings. Ultimately, it wants to see chronic pain recognised as a condition in its own right — and made a national health priority. "Currently, we don't recognise pain as a condition in its own right; we recognise it as a symptom. What that means is that not only is chronic pain invisible to society, it's invisible in our health system data and in our policies," Ellis said. Ellis said recognising chronic pain in its own right would increase awareness of the condition, to guide adequate funding and resources. SBS News has contacted the federal health department for comment. It's understood the latest report will be presented to parliament later this week. For Stevenson, having access to early diagnosis and complex care can make an "extraordinary difference". "It means that someone who may otherwise be bedridden for weeks and weeks on end can actually participate in society, can maintain a healthy work-life balance, and can go about their days as a person living as pain free as possible, which surely we all deserve."
ABC News
an hour ago
- ABC News
Federal funding for algal bloom, but no national disaster declared
The Federal Government has pledged $14 million to assist South Australia as it continues to deal with a toxic algal bloom outbreak, but has stopped short of declaring it a national disaster.
News.com.au
4 hours ago
- News.com.au
Health Check: On Lamington Day, biotechs serve up their chocolate-dipped quarterly morsels
Today's news is all sweet on trial progress, revenue and cash Amplia to raise capital after runaway share performance Tryptamine starts binge eating 'magic mushie' trial Today is National Lamington Day and biotechs are serving up a solid sponge-like base of news encased in chocolate and coconut – occasionally interspersed with a jam layer. Hold the cream and pink jelly though – it just doesn't work. Like so many drug discoveries, the lamington had serendipitous origins. The story goes that one of Queensland governor Lord Lamington's maids was serving up a yellow sponge, but accidentally dunked it into molten chocolate. Lord Lammo recommended the squares to be rolled into coconut shavings for ease of eating – and the rest is history. As is this non-sequitur. Now onto the biotech news. Lumos glows after last week's mega deal Point-of-care diagnostics house Lumos Diagnostics (ASX:LDX) reports revenue of $12.4 million for the year to June 30, up 12%. June quarter revenue declined 26% to $2.6 million, owing to the end of the US flu season. Lumos reported cash outflows of US$1.7 million for the quarter, taking June 30 cash to US$2 million. Investor interest has focused on last week's mega US distribution deal with Phase Scientific, which could deliver Lumos up to US$317 million ( $487 million) over six years. This pertains to the company's bacterial-versus-viral rapid lateral flow test, Febridx. Lumos has also signed a term sheet for a $5 million loan facility, proffered by shareholders Tenmile Ventures (Andrew Forrest) and Ryder Capital. At its discretion, Lumos can draw down the facility over the next 12 months. Cleo eyes FDA approval for ovarian cancer assay Still on diagnostics, Cleo Diagnostics (ASX:COV) says it aims to submit a US Food & Drug Administration (FDA) marketing approval application for its ovarian cancer assay next year. The company is on track to complete a supportive US trial in the December quarter. Thanks to government grants and tax incentives, Cleo reported cash inflows of $38,000, taking end of quarter cash to $6.46 million. Turning to drug development, genetic disease specialist PYC Therapeutics (ASX:PYC) reports cash outflows of $17.6 million. At quarter's end the company still had cash of $153 million. The company has dosed the first patient in a combined phase 1a/2b trial for polycystic kidney disease. PYC has achieved 'alignment' with the FDA on the structure of a registrational trial for its lead program, the blinding eye disease retinitis pigmentosa type 11. The company believes the regulator will require only a phase II trial. Tryptamine BEDS down eating disorder trial Psychedelic medicines house Tryptamine Therapeutics (ASX:TYP) has started recruiting patients for a world-first binge eating disorder (BED) study. In the open-label trial, 12 patients will be administered intravenously infused psilocybin, combined with psychotherapy. Melbourne's Swinburne University is undertaking the study, with first dosing this quarter and top line results due by the end of the year. BED is the most common eating disorder in the US and second most prevalent in Australia here. The condition can result in depression, anxiety, post-traumatic stress disorder and compulsive behaviour. Amplia passes the hat Meanwhile Amplia (ASX:ATX) shares this morning entered trading halt, ahead of a share placement and share purchase plan. Amplia thus continues the rich tradition of companies leveraging clinical trial results, in this case its stunning data for hard-to-treat pancreatic disease. Amplia has reported 17 'partial response' rates in it Accent trial, in 17 out of 55 advanced disease patients. A confirmed partial response is tumour shrinkage of more than 30%, sustained for two or more months with no new cancerous lesions detected. Amplia is testing AMP-945 (narmafotinib). AMP-945 appears to inhibit the protein FAK, which is overexpressed in pancreatic cancers. Amplia shares have surged 376% in the past 12 months, but investors still value the company at a modest $110 million. As of the end of March, Amplia had cash of $10.8 million. 'Perplexed' Imugene laments soft-as-a-sponge share price Imugene (ASX:IMU) chairman Paul Hopper hopes the company's lamington-soft share price will 'do an Amplia' (our words) and reflect the company's progress with its multiple cancer trials. The company last Monday announced its phase 1b study for an aggressive blood cancer had resulted in two additional 'complete responses' (that is, the tumours disappeared). Imugene is trialing Azer-cel, its allogeneic Car-T drug made from healthy donor T-cells rather than the patient's. Naturally, Imugene announced a $22.5 million and share purchase plan for up to $15 million. On reinstatement, the shares lost 4.5 cents, or 10%, taking the loss over the past year to around 80%. This allows for a one for 34 share consolidation. 'We are very disappointed with the share price performance,' Hopper says. 'We are perplexed why we had such a lukewarm reception to the earlier data at the start of year.' Cashed up for pivotal trial But with the share raising in train, Imugene investors should no longer fear that such a dilutionary event is around the corner. Post raising Imugene should have cash of $64 million, with management costing a 60-80 patient pivotal trial at $30-40 million. If approved, Azer-cel would be the first commercial allogenic Car-T treatment, enabling mass produced, off-the-shelf therapies. 'We are in active discussions with partners on the strategy for developing the drug and getting it approved,' Hopper says. Shares settle in orbit after last week's Meso-blast off Mesoblast (ASX:MSB) shares have taken a breather after Friday's 35% surge on the back of initial US sales of its first US-approved stem cell product. The company reported unaudited June quarter revenue of US$13.2 million ($20.3 million) for Ryoncil, its treatment for childhood graft-versus-host disease. The FDA approved Ryoncil in December last year. Mesoblast founder and CEO Prof Silviu Itescu points to higher sales in the current quarter, given US Centres for Medicare and Medicaid Services coverage became effective on July 1. The company has signed up more than 25 transplant centres and hopes to enlist all 45 priority centres by October. Bell Potter analyst John Hester says the sales were in line with the firm's expectations. 'The figure is inclusive of sales to the distributor, nevertheless it represents a reasonable proxy for hospital demand.' The firm values Mesoblast at $3.50 a share, implying 55% of upside.
